Division of Urologic Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania.
Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania.
Cancer. 2018 Oct 1;124(19):3839-3848. doi: 10.1002/cncr.31582. Epub 2018 Sep 12.
Partial nephrectomy (PN) is recommended for localized T1a (≤4 cm) renal masses and is preferred over radical nephrectomy (RN) for amenable T1b/T2 (>4 cm) tumors. The objective of the current study was to assess overall survival (OS) differences between PN and RN in patients with T1 and T2 renal cell carcinoma (RCC).
The National Cancer Data Base was queried for patients with T1 and T2 RCC who underwent PN or RN from 2004 to 2014. Trends in surgery were evaluated using Cochran-Armitage tests. Differences in OS were assessed using adjusted Kaplan-Meier methods. The effects of procedure on OS were analyzed using propensity score-based, weighted Cox proportional hazards models.
In total, 212,016 patients with T1 and T2 RCC who underwent either RN (59.7%) or PN (40.3%) were included. The use of PN rose from 2004 to 2014 (T1a: from 40.6% to 71.4%; T1b/T2: from 8.4% to 26.5%; P < .01). Adjusted 5-year OS was longer for patients who underwent PN in both subsets, although effect magnitude was reduced in the T1b/T2 cohort (T1a: 89.6% vs 85.1%; hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.70-0.75; P < .01; T1b/T2: 82.5% vs 80.8%; HR, 0.88; 95% CI, 0.83-0.94; P = .01). The benefit of PN on OS diminished as age and time from diagnosis increased; no OS improvement was observed in patients age ≥75 years who had T1b/T2 tumors (HR, 0.89; 95% CI, 0.76-1.06).
Receipt of PN is associated with improved OS in patients with T1a RCC. No procedure-related differences in OS were observed for patients age ≥75 years who had tumors measuring >4 cm. Decisions to undergo PN for T1b/T2 tumors should be based on individualized risk assessment.
部分肾切除术 (PN) 被推荐用于局部 T1a(≤4cm)肾肿瘤,并且对于可治疗的 T1b/T2(>4cm)肿瘤,PN 优于根治性肾切除术 (RN)。本研究的目的是评估在 T1 和 T2 肾细胞癌 (RCC) 患者中,PN 和 RN 之间的总生存 (OS) 差异。
从 2004 年至 2014 年,国家癌症数据库中检索接受 PN 或 RN 的 T1 和 T2 RCC 患者。使用 Cochran-Armitage 检验评估手术趋势。使用调整后的 Kaplan-Meier 方法评估 OS 差异。使用基于倾向评分的加权 Cox 比例风险模型分析手术对 OS 的影响。
共纳入 212016 例接受 RN(59.7%)或 PN(40.3%)治疗的 T1 和 T2 RCC 患者。PN 的使用率从 2004 年到 2014 年上升(T1a:从 40.6%到 71.4%;T1b/T2:从 8.4%到 26.5%;P<.01)。尽管在 T1b/T2 队列中,效应幅度减小,但接受 PN 的患者的 5 年 OS 更长(T1a:89.6% vs 85.1%;危险比[HR],0.73;95%置信区间[CI],0.70-0.75;P<.01;T1b/T2:82.5% vs 80.8%;HR,0.88;95% CI,0.83-0.94;P=.01)。PN 对 OS 的益处随着年龄和诊断后时间的增加而减小;对于 T1b/T2 肿瘤且年龄≥75 岁的患者,未观察到 OS 改善(HR,0.89;95% CI,0.76-1.06)。
在 T1a RCC 患者中,接受 PN 与改善 OS 相关。对于 T1b/T2 肿瘤且年龄≥75 岁的患者,PN 在 OS 方面没有差异。对于 T1b/T2 肿瘤,应基于个体化风险评估来决定是否进行 PN。